News About: Pharm. Industry
Flexible small package system over drug eyed
The current small-package drugs system will be flexibly applicable to 2,200 medicines under mutual consultation between the Korean Pharmaceutical Association and drug makers, according to the Korea Food and Drug Admin...
Price cuts corner local drugmakers
With multinationals taking up three-quarters of the local drug market, Korean makers will be unable to develop their own drugs if the government’s pressure to reduce medication costs continues, according to market ins...
Dulcolax marketing lures Korean drug makers
Boehringer Ingelheim Korea is seeking a promising Korean partner to market its leading product Dulcolax, which has been distributed by Zuellig Pharma Korea.
Boehringer is said to select one Korean company as its pa...
AstraZeneca to conduct Phase II study for olaparib
The battle against cancer seems to be on the verge of a major step forward. The success of a new class of drugs “PARP inhibitors” in destroying the disease points to a new direction in the development of anticancer dr...
Latin America, emerging markets for Korean drug manufacturers
Intensifying generic competition and regulatory developments in Latin America are making these markets more attractive for Korean pharmaceutical companies, according to a local report.
Korea Trade Investment Promot...
Drug price poses dilemma
The government’s plan to evaluate the economic effectiveness of existing insurance-covered medicines has posed a new dilemma for those who are involved in drug prices in pharmaceutical firms.
“The government’s pre...
Green Cross US FDA OK to test new anti-Parkinsonian drug candidate
Green Cross Corporation said on February 10 it has received approval from the U.S. Food and Drug Administration to start an early-stage human trial of GCC1290K for the treatment of Parkinson’s disease.
The company ...
Government’s more active role urged
The government is taking a carrot-and-stick approach to the local pharmaceutical industry, by encouraging development of new drugs with possible tax incentives on one hand and forcing two pharmaceutical firms to suspe...
Green Cross, CGV to promote Omi Menturm
Green Cross Corp. has intensified its marketing efforts for Omi Menturm, a lip care product, in collaboration with a local multiplex theater “CGV”.
The company says a total of 30,000 Omi Menturm products will be of...
Health insurance to cover cost-effective antihypertensive agents
The Health Insurance Review Agency (HIRA) has unveiled its plan to include cost-effective hypertensive drugs only into the eligible health insurance list.
In a recent information session, a HIRA official said it wi...
